본문 바로가기
KERD
논문KCI 등재

아밀로이드 표적 알츠하이머치매 치료제

Amyloid-Targeting Drugs for the Treatment of Alzheimer Disease

이애영
대한신경과학회 (Korean Neurological Association)|2021.08|대한신경과학회지 (Journal of the Korean Neurological Association)|제39권 제3호|pp. 134-140

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Alzheimer's diseaseImmunotherapyAmyloid β
주제분류신경과학

초록

Alzheimer’s disease (AD) is the most common cause of dementia, characterized by cognitive impairment, neurobehavioral changes, and loss of functional ability. Current therapeutic options for AD are limited to medications that contribute to modest symptomatic improvement. The amyloid β (Aβ) peptide is central to the pathogenesis, so that immunotherapy targeting Aβ has been focused as a putative disease-modifying treatment for AD. In this review, I review the ongoing Aβ -directed immunotherapies, including aducanumab, which is the new AD medication since 2003 as well as the first disease-modifying treatment on the market approved by the Food and Drug Administration.

Abstract

Alzheimer’s disease (AD) is the most common cause of dementia, characterized by cognitive impairment, neurobehavioral changes, and loss of functional ability. Current therapeutic options for AD are limited to medications that contribute to modest symptomatic improvement. The amyloid β (Aβ) peptide is central to the pathogenesis, so that immunotherapy targeting Aβ has been focused as a putative disease-modifying treatment for AD. In this review, I review the ongoing Aβ -directed immunotherapies, including aducanumab, which is the new AD medication since 2003 as well as the first disease-modifying treatment on the market approved by the Food and Drug Administration.

참고문헌 (48)

  1. "National Institute of Dementia"[URL]
  2. Bartus R, "The cholinergic hypothesis of geriatric memory dysfunction", Science, 217, pp.408~414 (1982)
  3. Long JM, "Alzheimer disease: an update on pathobiology and treatment strategies", Cell, 179, pp.312~339 (2019)
  4. Shinji M, "Efficacy and safety of cholinesterase inhibitors for mild cognitive impairment: a systematic review and meta-analysis", J Alzheimer's Dis, 71, pp.513~523 (2019)
  5. Hardy JA, "Alzheimer’s disease: the amyloid cascade hypothesis", Science, 256, pp.184~185 (1992)
  6. Selkoe DJ, "The amyloid hypothesis of Alzheimer’s disease at 25 years", EMBO Mol Med, 8, pp.595~608 (2016)
  7. Vaz M, "Alzheimer’s disease: recent treatment strategies", Eur J Pharmacol, 887, pp.173554~ (2020)
  8. Foroutan N, "Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer’s disease: a systematic review and network meta-analysis", Clin Investig Med, 42, pp.53~65 (2019)
  9. Lozupone M, "Anti-amyloid-β protein agents for the treatment of Alzheimer's disease:an update on emerging drugs", Expert Opin Emerg Drugs, 25, pp.319~335 (2020)
  10. Hong W, "Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer’s disease brain", Acta Neuropathol, 136, pp.19~40 (2018)
  11. Panza F, "A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease", Nat Rev Neurol, 15, pp.73~88 (2019)
  12. Hanseeuw BJ, "Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study", JAMA Neurol, 76, pp.915~924 (2019)
  13. Tolar M, "Neurotoxic soluble amyloid oligomers drive Alzheimer’s pathogenesis and represent a clinically validated target for slowing disease progression", Int J Mol Sci, 22, pp.6355~ (2021)
  14. Maria MA, "BACE-1 and gamma-secretase as therapeutic targets for Alzheimer's disease", Pharmaceuticals, 12, pp.41~ (2019)
  15. Wang Q, "Inhibition of amyloid-beta aggregation in Alzheimer's disease", Curr Pharm Des, 20, pp.1223~1243 (2014)
  16. Sperling R, "Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup", Alzheimers Dement, 7, pp.367~385 (2011)
  17. Holmes C, "Long‐term effects of Abeta42 immunization in Alzheimer's disease:follow‐up of a randomised, placebo‐controlled phase I trial", Lancet, 372, pp.216~223 (2008)
  18. Orgogozo JM, "Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization", Neurology, 61, pp.46~54 (2003)
  19. van Dyck CH, "Anti-amyloid-β monoclonal antibodies for Alzheimer's disease: pitfalls and promise", Biol Psychiatry, 83, pp.311~319 (2018)
  20. Panza F, "Bapineuzumab: anti‐beta‐amyloid monoclonal antibodies for the treatment of Alzheimer's disease", Immunotherapy, 2, pp.767~782 (2010)
  21. Imbimbo BP, "Solanezumab for the treatment of mild-to-moderate Alzheimer's disease", Expert Rev Clin Immunol, 8, pp.135~149 (2012)
  22. Doody RS, "Phase 3 trials of solanezumab for mild-tomoderate Alzheimer’s disease", N Engl J Med, 370, pp.311~321 (2014)
  23. Delrieu J, "Gantenerumab for the treatment of Alzheimer's disease", 12, pp.1077~1086 (2012)
  24. Sevigny J, "The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease", Nature, 537, pp.50~56 (2016)
  25. Ostrowitzki S, "A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease", Alzheimers Res Ther, 9, pp.95~ (2017)
  26. Logovinsky V, "Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody", Alzheimers Res Ther, 8, pp.14~ (2016)
  27. Hey JA, "Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain", CNS Drugs, 32, pp.849~861 (2018)
  28. Young SC, "A systematic review of antiamyloidogenic and metal-chelating peptoids: two structural motifs for the treatment of Alzheimer's disease", Molecules, 23, pp.296~ (2018)
  29. Hashimoto T, "Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid peptide", J Neurosci, 32, pp.15181~15192 (2012)
  30. Cedarbaum JM, "Rationale for use of the clinical dementia rating sum of boxes as a primary outcome measure for Alzheimer’s disease clinical trials", Alzheimers Dement, 9, pp.45~55 (2013)
  31. Sevigny J, "Addendum: the antibody aducanumab reduces Aβ plaques in Alzheimer’s disease", Nature, 546, pp.564~ (2017)
  32. Swanson CJ, "A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Abeta protofibril antibody", Alzheimers Res Ther, 13, pp.80~ (2021)
  33. Klein G, "Gantenerumab reduces amyloid-beta plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis", Alzheimers Res Ther, 11, pp.101~ (2019)
  34. Mintun MA, "Donanemab in early Alzheimer’s disease", N Engl J Med, 384, pp.1691~1704 (2021)
  35. Cummings J, "Aducanumab produced a clinically meaningful benefit in association with amyloid lowering", Alzheimer's Res Ther, 13, pp.98~100 (2021)
  36. "221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)"[URL]
  37. "221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)"[URL]
  38. "Biogen and eisai to discontinue phase 3 ENGAGE and EMERGE trials of aducanumab in Alzheimer’s disease" (2019)[URL]
  39. "Biogen plans regulatory filing for aducanumab in Alzheimer’s disease based on new analysis of larger dataset from phase 3 studies" (2019)[URL]
  40. Haeberlein SB, "Emerge and engage topline results: phase 3 studies of aducanumab in early Alzheimer’s disease", Alzheimer’s Dement, 16(S9), pp.e047259~ (2020)
  41. Alexander GC, "Evaluation of aducanumb for Alzheimer disease. Scientific evidence and regulatory review involving efficacy, safety, and futility", JAMA, 325, pp.1717~1718 (2021)
  42. Arnold C, "Post-hoc analysis could give new life to the Alzheimer's drug aducanumab", Nat Med (2020)
  43. "Demonstrating substantial evidence of effectiveness for human drug and biological products" (2019)[URL]
  44. Morant AV, "Characteristics of single pivotal trials supporting regulatory approvals of novel non-orphan, non-oncology drugs in the European Union and United States from 2012-2016", Clin Transl Sci, 12, pp.361~370 (2019)
  45. Andrews JS, "Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials", Alzheimers Dement (N Y), 5, pp.354~363 (2019)
  46. "Request for an Office of Inspector General investigation of the FDA’s inappropriate close collaboration with Biogen before and after the submission of the biologics license application for aducanumab for treatment of Alzheimer’s disease"[URL]
  47. VandeVrede L, "Symptomatic amyloid-related imaging abnormalities in an APOE ε4", ε4 patient treated with aducanumab, 2020, pp.12, e12101~
  48. Sakai K, "Aβ immunotherapy for Alzheimer's disease", Brain Nerve, 65, pp.461~468 (2013)

관련 논문AI추천

알츠하이머병에서 항아밀로이드 치료제 개발의 여정과 최근 임상적 성과윤현철대한생물정신의학회 · 생물정신의학2025 · 제32권 제2호다시 보는 알츠하이머병의 아밀로이드 가설김병수대한생물치료정신의학회 · 생물치료정신의학2014 · 제20권 제3호알츠하이머병에서 임상약물시험의 최신 동향강희영, 박경원대한신경과학회 · 대한신경과학회지2015 · 제33권 제4호알츠하이머병의 최신지견이석범, 이정재대한생물정신의학회 · 생물정신의학2016 · 제23권 제2호새로운 알츠하이머 치료제의 안전성 유효성에 관한 체계적 문헌고찰박신웅, 손현순, 심미경, 장하린한국임상약학회 · 한국임상약학회지2023 · 제33권 제4호알츠하이머 치매 약물치료의 현황과 미래김성윤대한신경정신의학회 · 신경정신의학2018 · 제57권 제1호

이 간행물의 다른 논문 (30건)

운동신경세포병의 임상 척도박진성, 성정준, 오성일, 김승현pp. 77-86군발두통 치료의 최신지견조수진, 손종희, 이미지pp. 113-120뇌졸중 연구에서 자연어처리와 텍스트 마이닝의 적용김철호pp. 121-128커피, 담배, 술이 파킨슨병에 미치는 영향설원기, 김혜정, 손일홍pp. 129-133응급실을 방문한 의식장애의 원인: 코로나바이러스감염증-19 이전과 이후조용원, 김근태, 김동환, 전재천, 김인철, 김예림pp. 141-149
원문 보기